Rapamycin is something that doctors use to help prevent organ transplant rejection. Other uses for it are as a cancer drug and one that can treat a rare lung disease by coating it on coronary stents that are placed inside the patient. Its trade name is Rapamune and it has been researched for almost 50 years. Rapamycin is also sometimes called Sirolimus. Sirolimus was first discovered on Easter Island. It was first used as an anti-fungal medicine. Further research into it revealed that it had other extremely helpful properties including as an antiproliferative and immunosuppressive. It was after these discoveries that doctors stopped using it as an anti-fungal medicine as it could serve much more urgent and deadly health problems.
Dr. Mikhail Blagosklonny is a professor and researcher at the Roswell Park Cancer Institute. Headquartered in Buffalo, New York, he has been researching cancer drug therapies for many years. As the Editor-in-Chief of the online journal Oncotarget, he has also been researching aging issues and the role that Rapamycin might play in slowing down or even eliminating that process.
As one of the premier researchers in regards to Rapamycin and longevity, Dr. Blagosklonny has conducted research using this material extensively. His research has been conducted on mice and his findings have shown that the test subjects can handle tuberculosis better than the non-treated mice. Tests have also been conducted on humans and that shows that those people have an immunological rejuvenation after receiving Rapamycin. Further research is being done on marmoset monkeys.
As is commonly known, cancer occurs with more frequency in people that are older. Age and cancer seemed to be linked which is something that Dr. Mikhail Blagosklonny has researched. His research has been followed by others in the field of oncology. His goal is to discover new cancer drug therapies that are not nearly as destructive and painful as the conventional therapies are such as surgery and chemotherapy. He also seeks to reduce the cost of these therapies so that they are much more widely available.
As part of this new wave of cancer drug therapies, Dr. Mikhail Blagosklonny wants to find new drugs that will kill cancer cells while leaving non-cancerous cells alone. This will ultimately not only reduce the pain and suffering of those undergoing cancer treatment but it will also lead to much more effective cures than what are currently present. He has made a great deal of progress in this quest as have other researchers in his field of oncology. Dr. Mikhail Blagosklonny is a well-respected professor of oncology at the Roswell Park Cancer Institute. He has helped to educate a few generations of new doctors and researchers in his field of medicine. He has also continued to be a philanthropist who seeks to give back to others through his extensive research into helping people live long, healthier lives that will hopefully one day be completely free of disease.